Marinomed Biotech AG · VIE:MARI
Marinomed Biotech — Investor Presentation (October 2023)
39 slides from Marinomed Biotech's investor presentation, October 2023
Slide 1: Marinomed Biotech AG Corporate Presentation
Marinomed Biotech AG Corporate Presentation October 2023
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Contents
Contents 1. Company 4 2. Platforms, Pipeline 9 3. Strategic priorities & project status 17 4. Financials 22 5. Outlook 25 6. Financial calendar & IR contact 27 7. Appendix 28 © Marinomed Biotech AG 3
Slide 4: Company
Company Overview, Business Model, Equity Story © Marinomed Biotech AG 4
Slide 5: Marinomed at a glance
Marinomed at a glance Publicly listed biopharmaceutical company located in Korneuburg, Austria 2006 2008 2016 2019 2021 2022 Foundation Launch of Carragelose Invention of IPO and Marinosolv Marinosolv deal and Deal with Procter & Marinosolv clinical validation Solv4U launch Gamble 8.2% 8.0% Hermann
Slide 6: Business Model
Business Model Lean organization & growing existing business RESEARCH & DEVELOPMENT SALE OF GOODS Research & Pre-clinical Early clinical Supply chain Innovation development development organization Intellectual property High-value products Revenue through license deals Revenue through (upfront, mile
Slide 7: Equity Story
Equity Story Solid existing business, continued growth perspective through late-stage pipeline assets • Experienced management team • Solid revenue from marketed product portfolio • Three key assets in partnering: • Carragelose portfolio • Budesolv • Tacrosolv • Lean and efficient business model: co
Slide 8: Highlights year-to-date 2023
Highlights year-to-date 2023 Progress and new developments EUR 5.2 m Market Solv4U New products revenues (+7 %) authorization Partnership Carragelose eye Strong H1 For Carragelose With SPH Sine drops and allergy Carragelose nasal spray in Pharmaceutical blocker – launch revenues Mexico Laboratories
Slide 9: Platforms, Pipeline
Platforms, Pipeline © Marinomed Biotech AG 9
Slide 10: Platforms
Platforms • Polymer extracted from red seaweed • Solubilization of poorly water-soluble compounds • Forms non-specific layer that protects mucosa from viruses & • Significantly increases bioavailability allergens → multi-purpose • Allows dose reduction & faster onset of action • Favorable safety pro
Slide 11: Pipeline
Pipeline Including late-stage projects with low risk and high upside potential © Marinomed Biotech AG 11
Slide 12: MAM-1004-1/Budesolv
MAM-1004-1/Budesolv Superior nasal spray formulation of corticosteroid Budesonide • Marinosolv formulation: Solution instead of TNSS* before and after treatment day 1 suspension • Pivotal comparative Phase III study1 completed: 7,6 • Primary and secondary endpoints met 7,2 • ~85% reduced dose • Sign
Slide 13: MAM-1003-1/Tacrosolv
MAM-1003-1/Tacrosolv Best-in-class macrolide immunosuppressant – fully solubilized with Marinosolv Fully solubilized Tacrolimus Tacrolimus (FK506) Tacrosolv • Immunosuppressant widely used systemically after • Fully solubilized Tacrolimus organ transplantation • Better bioavailability than suspensio
Slide 14: Carragelose®
Carragelose® Protective layer against viruses and allergens – multi-use potential Viral respiratory diseases Carragelose Eye care • Broadly-active against several • Carragelose has excellent respiratory viruses moisturizing properties • Clinically validated1 • Eye drops can provide relief of dry eye
Slide 15: Carragelose® – Product portfolio
Carragelose® – Product portfolio Product Launch Active ingredients Claims Nasal spray for adults and children 1y+ 2008 1.2 mg/ml Carragelose Prophylactic and supportive treatment of viral Nasal spray for children 1y+ 2012 1.2 mg/ml Carragelose infections of the respiratory tract 1.2 mg/ml Carragelos
Slide 16: Solv4U overview
Solv4U overview PHASE I PHASE II PHASE III PHASE IV FEASIBILITY FORMULATION PRECLINICAL & TECH TRANSFER DEVELOPMENT CLINICAL STUDIES Enhanced solubility of target Optimize formulation & Target Product Profile (TPP) & Enable manufacturing at compound with Marinosolv® Provide non-GMP material for stud
Slide 17: Strategic priorities & project status
Strategic priorities & project status © Marinomed Biotech AG 17
Slide 18: Marinomed strategic priorities
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN • Long-term adherence to our mission MAM-1004-2 • Funding promising pipeline programs through own cash flows NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV BUDESOLV • Expanding business with
Slide 19: Immunology – focus on business development
Immunology – focus on business development Enable new partnerships and prepare launches Product Action item Status / next steps Continue ongoing BD efforts and Enable a near term partnership discussions with potential partners MAM-1004-1/Budesolv Treatment of severe allergic rhinitis Preparation for
Slide 20: Virology – growth strategy
Virology – growth strategy Expansion of territory, indication and product portfolio Product Action item Status / next steps Virus blocking OTC portfolio Existing Partnerships USA (Procter & Gamble), Mexico and USA → FDA registration Brazil (M81) Mexico → received market approval Brazil → ANVISA regi
Slide 21: Solv4U Technology Partnerships
Solv4U Technology Partnerships Increase BD activities and support ongoing partnerships Product Action item Status / next steps A series of feasibility projects have been completed - progress current Solv4U Increase BD activities - continue projects to licensing partnerships Marinosolv for external c
Slide 22: Financials
Financials H1 2023 © Marinomed Biotech AG 22
Slide 23: Record H1 revenues
Record H1 revenues Carragelose strong in H1 with post-pandemic slow-down of customer orders Development of half-yearly revenues (m€) Comments Historical numbers • Revenues rose from €4.9m to €5.2m (+7%) 2,1* • EBIT slightly decreased from €2.5m to €2.9m due to higher R&D expenses 5,8 6,3 6,4 4,5 4,9
Slide 24: Cash visibility into 2024
Cash visibility into 2024 Carragelose revenues reducing cash burn, repayment of loans ongoing •1 Operations mainly consisting of personnel costs and R&D expenses; MDR switch temporarily also contributing 1 1 2• Strong quarters in terms of Carragelose revenue contributing 1 significantly to reducing
Slide 25: Outlook
Outlook © Marinomed Biotech AG 25
Slide 26: Outlook
Outlook Continue strategy with focus on near-term revenues • Strong H1, H2 2023 Carragelose revenues impacted by post- pandemic effects Strengthen existing business • Drive Carragelose in the U.S., Mexico and others and partnerships to ensure • Launch Carragelose allergy and eye products in 2024 sus
Slide 27: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2023 November 21, 2023 Publication of the Results Q1-3 2023 Stephanie Kniep Investor Relations phone: +43 2262 90300 226 e-mail: [email protected] © Marinomed Biotech AG 27
Slide 28: Appendix
Appendix © Marinomed Biotech AG 28
Slide 29: Marinomed strategic priorities MAM-1003-1/Tacrosolv
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN MAM-1004-2 NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV MAM-1003-1/Tacrosolv BUDESOLV EYE DROPS & ALLERGY HIGH-VALUE PIPELINE ASSETS BUDESOLV SOLV4U CARRAGELOSE REVENUE-GENERATING CORE BUS
Slide 30: Attractive ophthalmic market
Attractive ophthalmic market Total target populations & market sizes Tacrosolv Allergic Herpetic stromal Vernal Dry eye disease conjunctivitis keratitis (HSK) keratoconjunctivitis US 49mn1 US 50mn4 US 18k7 US 33k7 EU5 59mn2 EU5 60mn5 EU5 18k7 EU5 162k7 US$ 6.5bn (2027)3 US$ 3.6bn (2028)6 US$ 300mn8
Slide 31: Marinomed strategic priorities MAM 1001-3 Eye Drops
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN MAM-1004-2 NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV BUDESOLV MAM 1001-3 EYE DROPS EYE DROPS & ALLERGY HIGH-VALUE PIPELINE ASSETS BUDESOLV SOLV4U CARRAGELOSE REVENUE-GENERATING CORE BUS
Slide 32: MAM-1001-3 eye drops
MAM-1001-3 eye drops Moisturizing eye drops complement Carragelose OTC portfolio • Certified medical device product (class IIa) for the relief of dry eyes • Carragelose has excellent lubricating properties & outstanding safety profile • Multidose, preservative-free product • With US$ 6bn1, eye care
Slide 33: Marinomed strategic priorities MAM-1001-4 allergy nasal spray
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN MAM-1004-2 NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV BUDESOLV MAM-1001-4 EYE DROPS & ALLERGY HIGH-VALUE PIPELINE ASSETS allergy nasal spray BUDESOLV SOLV4U CARRAGELOSE REVENUE-GENERATIN
Slide 34: Carragelose in allergy: Buffered Coldamaris pro
Carragelose in allergy: Buffered Coldamaris pro Significantly reduced symptoms TNSS median 180 min Rhinorrhea 9,1 2,3 8,9 2,2 8,7 2,1 p=0.028 p<0.05 Median TNSS 8,5 2 8,3 1,9 8,1 1,8 7,9 1,7 7,7 1,6 7,5 1,5 Callergin No treatment Callergin No treatment Both, total nasal symptom score and runny nose,
Slide 35: Marinomed strategic priorities SOLV4U
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN MAM-1004-2 NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV BUDESOLV EYE DROPS & ALLERGY HIGH-VALUE PIPELINE ASSETS BUDESOLV SOLV4U SOLV4U CARRAGELOSE REVENUE-GENERATING CORE BUSINESS SHORT TE
Slide 36: Solv4U Technology partnerships
Solv4U Technology partnerships Marinosolv solubilization technology to improve drug delivery and bioavailability • Suitable for solubilizing APIs mainly from We offer • Customized formulation development BCS Classes II and IV and NCE development • Feasibility studies • Production of samples for earl
Slide 37: The technology: Marinosolv
The technology: Marinosolv Solubility-enhancing agents enable aqueous formulations of hydrophobic compounds The different constituents of the Marinosolv matrix are individually composed for an optimized formulation of each drug substance. © Marinomed Biotech AG 37
Slide 38: Sustainability
Sustainability Marinomed contributes to sustainability goals and adheres to ESG • Reduction of active ingredient by using Marinosolv solubilization technology • Sustainability of company premises (e.g., solar energy) • Promote environmentally friendly supply chains ENVIRONMENT • Therapies for people
Slide 39: www.marinomed.com
www.marinomed.com 0) Marinomed
Marinomed Biotech — Investor Presentation (October 2023) on 6ix